Clinical trials: Relative Bioavailability
Malaria Prophylaxis
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin…
- Trial name
- AZCQ (NCT01100060)
- Testing
- azithromycin (AZ) microsphere, test chloroquine (CQ) formulation, azithromycin (AZ)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bioequivalence
Ibuprofen Bioavailability Trial With Oral Single Dose Administration.
The present study will be conducted in order to assess bioequivalence of the Test product (Ibuprofen 400 mg oral powder) and the Reference product 1 (Brufen 400 mg film-coated tablet), an approved market product in the European…
- Trial name
- NCT03018015
- Testing
- Ibuprofen 400 mg oral powder, Ibuprofen 400 mg film-coated tablet, Ibuprofen 400 mg soft capsule
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SocraTec R&D GmbH
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy
A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions
The purpose of this study is to compare the relative bioavailability of 3 mg Alprazolam Extended Release Tablets by Alpharma with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3…
- Trial name
- NCT00865657
- Testing
- Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy
Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects
Study to assess the amount of BIBR 953 ZW in urine after administration of 50 mg BIBR 1048 bid over three days each administered as four experimental formulations relative to drinking solution with and without coadministration of…
- Trial name
- NCT02170636
- Testing
- BIBR 1048 MS Capsule E, BIBR 1048 MS Capsule F, BIBR 1048 MS Capsule G
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants
Open label, randomized, 4-period crossover study with single doses of BMS-986141 given to healthy female subjects of non-childbearing potential and healthy males.
- Trial name
- NCT03035734
- Testing
- BMS-986141 Form A Tablet, BMS-986141 Form B tablet (low dose), BMS-986141 Form B tablet (high dose)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Rheumatoid Arthritis, Osteoarthritis
Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)
The purpose of this study is to demonstrate the relative bioavailability of Naproxen delayed-release tablets (375 mg).
- Trial name
- NCT00959439
- Testing
- Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.), Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sandoz
Pharmacokinetics, Bioavailability
Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005…
- Trial name
- NCT05967377
- Testing
- Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005 Sorafenib Tablet A - Period 1
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Healthy Volunteers
Study of BIIB091 Formulations in Healthy Participants
The primary objectives of this study are: to evaluate the pharmacokinetic (PK) profiles of BIIB091 modified release (MR) formulations in healthy participants after single dose administration in the fasted state (Part 1); to…
- Trial name
- NCT04564612
- Testing
- BIIB091, Rabeprazole, Itraconazole
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy
Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects
The objective was to assess the relative bioavailability of a pilot scale linagliptin 2.5 mg / metformin 1000 mg fixed dose combination (FDC) tablet in comparison with single tablets of linagliptin 2.5 mg and metformin 1000 mg…
- Trial name
- NCT02173639
- Testing
- BI 1356/metformin, BI 1356, Metformin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
The main objective of this trial is to investigate: the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs.
- Trial name
- NCT06193811
- Testing
- Avenciguat (BI 685509) (intended commercial formulation (iCF)), Avenciguat (BI 685509) (trial formulation 2 (TF2)), esomeprazole
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
PPI And Food Effect Study For PF-06463922 In Healthy Volunteers
The current study will be conducted in healthy adult subjects to evaluate the effect of proton pump inhibitor and food on pharmacokinetics of PF-06463922, to evaluate the bioavailability of the oral solution relative to the…
- Trial name
- NCT02569554
- Testing
- PF-06463922, rabeprazole
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198
To investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of multiple rising doses per day over 14 days and to explore the pharmacokinetics (PK) of BI 764198 after single and…
- Trial name
- NCT04102462
- Testing
- BI 764198
- Where
- Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Adrenal Insufficiency
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
This was a single centre, open label, randomised, two period, crossover study to evaluate the bioavailability of Chronocort® versus Cortef® immediate release hydrocortisone tablets in dexamethasone-suppressed healthy adult male…
- Trial name
- NCT03343327
- Testing
- Chronocort®, Cortef®
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Cough
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
This is an open-label study being conducted in healthy adults, to learn what happens to the study medicine (camlipixant) they are receiving in a person's body over time (a pharmacokinetic [PK] study).
- Trial name
- NCT07684586
- Testing
- Camlipixant
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects
The primary objective is to investigate the relative bioavailability of two newly developed tablet formulations of BI 1060469 vs BI 1060469 TF1 formulation.
- Trial name
- NCT02438696
- Testing
- BI 1060469, iFF, Test, BI 1060469, TF1, Reference, BI 1060469, TF2, Test
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers
This randomized, open-label, cross-over study will assess the bioavailability and safety of RO4995819 in healthy volunteers. Volunteers will receive two different formulations (tablet and capsule) of the study drug under fed and…
- Trial name
- NCT01901159
- Testing
- RO4995819
- Where
- France
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Vitamin B12 Deficiency
Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate
Folic acid, a form of the vitamin folate, is added to grain products in Canada to help reduce birth defects. Folic acid is the synthetic form of folate and is very stable (doesn't break down) when added to foods.
- Trial name
- NCT01584050
- Testing
- L-5-methyltetrahydrofolate (Metafolin ®), folic acid
- Where
- 2 sites in Canada, Malaysia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Healthy
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3 mg/24 h (Luye Pharma AG, Germany) and the marketed…
- Trial name
- NCT05853341
- Testing
- RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.